Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Drug development for malaria : novel approaches for prevention and treatment / / edited by Pravin Kendrekar
| Drug development for malaria : novel approaches for prevention and treatment / / edited by Pravin Kendrekar |
| Pubbl/distr/stampa | Weinheim, Germany : , : Wiley-VCH, , [2023] |
| Descrizione fisica | 1 online resource (395 pages) |
| Disciplina | 616.9362 |
| Soggetto topico |
Malaria - Treatment
Drug development |
| ISBN |
3-527-83058-8
3-527-83060-X |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright -- Contents -- Part I Introduction -- Chapter 1 Chronology of Drug Development for Malaria -- 1.1 Introduction -- 1.1.1 Life Cycle of Malaria (Adapted from CDC) -- 1.2 Malaria - Erstwhile Memories -- 1.2.1 Progress Fighting Malaria -- 1.3 Current Chemotherapy Used to Treat Malaria -- 1.3.1 Current Combination Therapy -- 1.4 Drug Resistance of Antimalarial Drugs -- 1.4.1 Detection of Drug Resistance -- 1.5 Newer Drugs Approved for Malaria Treatment -- 1.6 Current Approaches to Developing a Malaria Vaccine -- 1.6.1 Hope for Vaccine Lies in the Parasite Itself -- 1.7 Conclusion: The Path Forward -- 1.7.1 RTS, ‐S Vaccine: A New Tool with Potential for Africa -- References -- Part II Challenges and Opportunities in Malaria Therapy -- Chapter 2 Scientific Challenges and Treatment Opportunities in the Face of Shifting Malaria Epidemiology -- 2.1 Introduction -- 2.2 The Scientific Challenges Against Malarial Drug -- 2.3 Advances in Understanding and Managing Drug Resistance -- 2.3.1 Vector and Its Control -- 2.3.2 Parasite and Its Control -- 2.3.2.1 Malaria Vaccine -- 2.3.2.2 Antimalarial Drugs -- 2.4 Methods to Assess the Presence and Level of Drug Resistance -- 2.4.1 Therapeutic Efficacy of Antimalarial Drugs -- 2.4.2 Molecular Markers Associated with P. falciparum -- 2.5 Antimalarial Drugs Currently in Use and in the Pipeline -- 2.6 Future -- References -- Chapter 3 Emerging Formulation Technologies Against Malaria Resurgence -- List of Abbreviations -- 3.1 Introduction -- 3.1.1 Major Pathological Hallmarks of Malaria -- 3.1.2 Current Treatment Strategies -- 3.2 Pitfalls of the Current Treatment Regimen -- 3.2.1 Drug Resistance -- 3.2.2 High Drug Dose -- 3.2.3 Long‐Term Treatment -- 3.2.4 Recurrence and Reversion of Diseases -- 3.3 Nanotechnology‐Based Strategies for Targeting in Antimalarial Therapy.
3.3.1 Passive Targeting -- 3.3.2 Active Targeting -- 3.3.2.1 Hepatocyte Targeting -- 3.3.2.2 Erythrocyte Targeting -- 3.3.2.3 Brain Targeting -- 3.3.3 Rapid Diagnosis and Vector Control -- 3.4 Nano Formulations for Malarial Treatment -- 3.4.1 Lipid‐Based Nanoplatforms -- 3.4.1.1 Nanoemulsion -- 3.4.1.2 Self‐Emulsifying Drug Delivery System (SEDDS) -- 3.4.1.3 Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) -- 3.4.1.4 Liposome -- 3.4.2 Polymer‐Based Nanoplatforms for Malaria -- 3.4.2.1 Nanoparticles -- 3.4.2.2 Nanocapsules -- 3.4.2.3 Dendrimers -- 3.4.2.4 Micelles -- 3.4.2.5 Polymeric Hydrogel Nanoparticles -- 3.4.2.6 Nanosuspension -- 3.4.3 Organized Layer‐by‐Layer Assembly -- 3.4.4 Inorganic Nano‐architectonics -- 3.4.4.1 Metallic Platforms -- 3.4.4.2 Quantum Dots -- 3.4.4.3 Carbon Nanostructures -- 3.4.4.4 Bio‐ceramics -- 3.4.5 Bio‐inspired Nanocarriers -- 3.4.5.1 Vaccines Based on Bio‐inspired Nanocarriers -- 3.4.5.2 Bio‐engineered Strategy Based on Erythrocytes -- 3.4.6 Protein-Peptide‐Based Drug Delivery System -- 3.4.7 Stimuli‐Responsive Platforms for Malaria -- 3.4.7.1 pH‐Responsive Formulations -- 3.4.7.2 Thermo‐Responsive Formulations -- 3.4.7.3 Redox State Responsive Substances -- 3.4.7.4 Stimuli‐Responsive Liquid Crystalline Materials -- 3.5 Diagnostics -- 3.5.1 Stimuli‐Responsive Iron Oxide and Gold Nanoparticle Reagent System -- 3.5.2 Immunological Adjuvants -- 3.5.3 Nanofibers -- 3.6 Challenges in Clinical Translation of Nanomedicine -- 3.6.1 Biological Challenges -- 3.6.2 Biocompatibility and Safety -- 3.6.3 Challenges in Manufacturing Scale‐Up and Reproducibility -- 3.6.4 Analytical Characterization and Quality Control Challenges of Nano‐Formulations -- 3.6.5 Regulatory Challenges -- 3.6.6 Other Challenges -- 3.7 Summary and Future Perspective -- 3.8 Conclusion -- Acknowledgments -- References. Chapter 4 Targeted Drug Delivery for Antimalarial Therapy -- 4.1 Introduction -- 4.2 Remodelling of Parasite‐Infected Red Blood Cell (pRBC) -- 4.2.1 The Red Blood Cell Membrane (RBCM) -- 4.2.2 The Parasitophorous Vacuole Membrane (PVM) -- 4.2.3 The Parasite Plasma Membrane (PPM) -- 4.3 The Emergence of Resistance and Antimalarial Therapy Approach -- 4.4 Nanocarriers for Antimalarial Drug Delivery -- 4.4.1 Liposomes -- 4.4.2 Solid Lipid Nanoparticles (SLNs) -- 4.4.3 Nanostructured Lipid Carriers (NLCs) -- 4.4.4 Nano‐emulsions (NEs) -- 4.4.5 Polymeric Nanoparticles -- 4.5 Targeted Antimalarial Drug Delivery Systems -- 4.5.1 Passive Drug Targeting with Conventional Nanocarriers -- 4.5.2 Active Drug Targeting with Surface‐Modified Nanocarrier -- 4.6 Conclusion: Moving Towards the Future -- Acknowledgements -- References -- Chapter 5 The Imminent Threat of Antimalarial Drug Resistance -- 5.1 Introduction -- 5.2 Antimalarial Drugs: An Overview -- 5.3 The Evolution of CQ Resistance -- 5.3.1 Mechanism of Action of CQ -- 5.3.2 Basis of CQ Resistance -- 5.3.3 Prevalence of CQ Resistance -- 5.3.4 WHO Guidelines to Use CQ -- 5.4 Impact of Sulfadoxine-Pyrimethamine Resistance -- 5.4.1 Mechanism of Action of SP -- 5.4.2 SP Resistance -- 5.4.3 Distribution of DHPS and DHFR Mutation Across Globe -- 5.4.3.1 dhfr -- 5.4.3.2 dhps -- 5.4.4 WHO Guidelines to Use SP -- 5.4.4.1 IPTp Guidelines -- 5.4.4.2 IPTi Guidelines -- 5.5 ACT Resistance -- 5.5.1 Mechanism of Action of ART -- 5.5.2 ART Resistance and ACT Failure -- 5.5.3 WHO Guidelines -- 5.6 Conclusion: The Road Ahead -- References -- Chapter 6 Current Therapies and New Drug Targets for the Future Drug Development of Drug Resistant Malaria -- 6.1 Introduction -- 6.2 Life Cycle of Plasmodium falciparum -- 6.3 Current Antimalarial Therapy and Their Shortcomings -- 6.4 Drug Targets for Current Antimalarial Therapy. 6.4.1 Drug‐Resistant Malaria and Identification of New Targets -- 6.4.1.1 Food Vacuole as Drug Targets -- 6.4.1.2 Shikimic Acid Pathway Targeting -- 6.4.1.3 Targeting Folate Pathway and Methionine Synthesis Pathway -- 6.4.1.4 Glycolytic Pathway Inhibition -- 6.4.2 Mitochondria as Drug Targets -- 6.4.2.1 Targeting Electron Transport Chain -- 6.4.2.2 Inhibition of Dihydroorate Dehydrogenase -- 6.5 Future Drug Development for the Treatment of Malaria -- 6.5.1 Benefits of Nanocarriers -- 6.5.2 Lipid‐Based Drug Delivery -- 6.5.3 Liposomes (as Nanocarriers) -- 6.5.4 Nanostructured Lipid Carriers -- 6.5.5 Solid Lipid Nanocarriers -- 6.6 Conclusion -- References -- Part III Drug Development -- Chapter 7 Assays for Antimalarial Drug Discovery -- 7.1 Introduction -- 7.2 In Vitro Assays for Antimalarial Drug Discovery -- 7.2.1 Schizont Maturation Inhibition Assay (Microscopic Test) -- 7.2.2 In Vitro Micro Test Technique -- 7.2.3 Radioisotope Assay -- 7.2.4 Colorimetric Assay (Plasmodium Lactate Dehydrogenase Assay [pLDH]) -- 7.2.5 ELISA‐Based Methods -- 7.2.5.1 DELI Assay -- 7.2.5.2 Assay Based on Histidine‐Rich Protein II (HRP II) of P. falciparum -- 7.2.6 Flow Cytometry -- 7.2.7 Fluorometric Assay -- 7.2.8 β‐Hematin Formation (Haemozoin Test) -- 7.2.9 Drug Interaction Assay and Isobologram Analysis -- 7.2.10 PCR‐Based Methods -- 7.2.11 In Vitro Assays Targeting Exo‐erythrocytic and Sexual Stages of the Parasite -- 7.2.11.1 Exo‐erythrocytic Schizontocidal Assay -- 7.2.11.2 Ex‐flagellation Assay -- 7.3 In Vivo Assays for Antimalarial Drug Discovery -- 7.3.1 Peters' 4‐Day Test -- 7.3.2 Dose Ranging Full 4‐Day Test -- 7.3.3 Onset/Recrudescence Test -- 7.3.4 Preventive Test -- 7.3.5 Curative Test -- 7.3.6 Hill's Test for Causal Prophylaxis and Residual Activity -- 7.3.7 Assays with P. berghei Green Fluorescent Protein (PbGFP). 7.3.8 Assays Employing Immunocompromised Mice -- 7.3.9 Primate Models for In Vivo Studies -- 7.3.10 Sporontocidal Assays -- 7.3.11 Anti‐sporozoite Assay -- 7.4 Ex Vivo Assays for Antimalarial Drug Discovery -- 7.5 Assays for Assessment of In Vitro Toxicity -- 7.5.1 MTT Assay -- 7.5.2 XTT Assay -- 7.5.3 LDH (Lactate Dehydrogenase) Assay -- 7.5.4 Protein Content Assay -- 7.5.5 Neutral Red Uptake Assay (NRU) -- 7.6 Assays for Assessment of In Vivo Toxicity -- 7.6.1 Acute Toxicity -- 7.6.1.1 Limit Test of Lorke -- 7.6.1.2 Up and Down Procedure -- 7.6.2 Chronic Toxicity -- 7.7 Conclusion -- References -- Chapter 8 Aminoacyl‐tRNA Synthetases as Malarial Drug Targets: A Structural Biology Perspective -- 8.1 Introduction -- 8.2 Pf/Pv‐aaRSs -- 8.2.1 Pf/Pv Genome -- 8.2.2 Aminoacyl‐tRNA Synthetases (aaRSs) -- 8.3 Aminoacyl‐tRNA Synthetases as Druggable Targets -- 8.4 Biochemical Screening of Drug Libraries -- 8.4.1 Colorimetric Assays -- 8.4.2 Enzyme‐Coupled Assays -- 8.4.3 Luciferase Assay -- 8.4.4 Assay to Test Synthetic as Well as Proofreading Activity -- 8.5 Structurally Validated Pf/Pv‐aaRSs as Drug Targets -- 8.5.1 Lysyl‐tRNA Synthetase (KRS) -- 8.5.2 Prolyl‐tRNA Synthetase -- 8.6 Potential Drug Targets Pf/Pv‐aaRSs -- 8.6.1 Leucyl‐tRNA Synthetase (LRS) -- 8.7 Arginyl‐tRNA Synthetase (RRS) -- 8.7.1 Tryptophanyl‐tRNA Synthetase (WRS) -- 8.7.2 Tyrosyl‐tRNA Synthetase -- 8.8 Others -- 8.9 Conclusion: The Road Ahead -- References -- Chapter 9 Natural Products as a Source for Antimalarial Drug Development Process - An Overview -- 9.1 Introduction -- 9.2 Phytochemicals as Antimalarial Agents: Recent Developments -- 9.2.1 Alkaloids -- 9.2.2 Terpenes -- 9.2.2.1 Sesquiterpene Lactones -- 9.2.2.2 Diterpenes -- 9.2.2.3 Triterpenes -- 9.2.2.4 Steroids and Others -- 9.2.3 Polyphenols -- 9.2.3.1 Biflavonoids -- 9.2.3.2 Prenylated Flavonoids -- 9.2.3.3 Other Flavonoids. 9.3 Traditional System of Medicine and Malaria. |
| Record Nr. | UNINA-9910830804403321 |
| Weinheim, Germany : , : Wiley-VCH, , [2023] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Global trends in care seeking and access to diagnosis and treatment of childhood illnesses / / Adam Bennett [and three others]
| Global trends in care seeking and access to diagnosis and treatment of childhood illnesses / / Adam Bennett [and three others] |
| Autore | Bennett Adam |
| Pubbl/distr/stampa | Rockville, Maryland, USA : , : ICF International, , 2015 |
| Descrizione fisica | 1 online resource (iv, 122 pages) : color illustrations, color map |
| Collana | DHS working papers |
| Soggetto topico |
Demographic surveys - Statistical methods
Health surveys - Statistical methods Child health services Children - Health and hygiene Diarrhea in children - Treatment Malaria - Treatment Respiratory infections in children - Treatment |
| Soggetto genere / forma | Statistics. |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910711732203321 |
Bennett Adam
|
||
| Rockville, Maryland, USA : , : ICF International, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecular Approaches to Malaria / / edited by Irwin W. Sherman
| Molecular Approaches to Malaria / / edited by Irwin W. Sherman |
| Pubbl/distr/stampa | Washington, District of Columbia : , : John Wiley & Sons, Inc., , 2014 |
| Descrizione fisica | 1 online resource (xviii, 542 pages) : illustrations |
| Disciplina | 614.532 |
| Soggetto topico |
Malaria - Molecular aspects
Molecular biology Malaria - Treatment |
| ISBN | 1-68367-190-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The life of plasmodium: an overview / I.W. Sherman Plasmo DB / D. Roos -- Making a home for plasmodium post-genomics: ultrastructural organization of the blood stages / L. Bannister, G. Margos and J. Hopkins -- Genetic manipulation of plasmodium falciparum / A. Cowman and B. Crabb -- The transcriptome of the malaria parasite, plasmodium falciparum / K. Le Roch and E. Winzeler -- The plasmodium proteome / J. Johnson and J. Yates -- Evolutionary history and population genetics of human malaria parasites / M. Zilversmit and D. Hartl -- Merozoite / J. Barnwell and M. Galinski -- Ookinete / J. Vinetz -- The sporozoite / R. Sinden and K. Matuschewski -- Gametocytes and gametes / P. Alano and O. Billker -- Molecular approaches to malaria: glycolysis in asexual stage parasites / B. Woodrow and S. Krishna -- The mitochondrion / A. Vaidya -- Trafficking and the TVN / K. Haldar [and others] -- The apicoplast / S. Ralph -- Protein kinases regulating plasmoidum proliferation and development / C. Doerig. -- Proteases and hemoglobin degradation / P. Rosenthal -- Plasmodium lipids: metabolism and function / H. Vial and C. Ben Mamoun -- Plasmodium ribosomes and opportunities for drug intervention / T. McCutchan and I. Sharma -- Oxidative stress and antioxidant defence in malaria parasites / K. Becker, S. Koncarevic, and N. Hunt -- New permeation pathways / S. Thomas and S. Egée -- Molecular aspects of antigenic variation in plasmodium falciparum / P. Horrocks [and others] -- Mechanisms of drug action and resistance / A. Uhlemann, Y. Yuthavong and D.A. Fidock -- Human genetic determinants of resistance to malaria / B.P. Kwiatkowski and G. Luoni -- Progress in development of a vaccine to aid malaria control / S. Moorthy and F. Dubovsky -- The anopheles gambiae genome / H. Collins and C.A. Hill -- The transcriptome of human malaria vectors / O. Marinotti and A.A. James. |
| Record Nr. | UNINA-9910830578003321 |
| Washington, District of Columbia : , : John Wiley & Sons, Inc., , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Preventing malaria during pregnancy in Sub-Saharan Africa : determinants of effective IPTp delivery / / Lia Florey
| Preventing malaria during pregnancy in Sub-Saharan Africa : determinants of effective IPTp delivery / / Lia Florey |
| Autore | Florey Lia |
| Pubbl/distr/stampa | Calverton, Maryland, USA : , : ICF International, , 2013 |
| Descrizione fisica | 1 online resource (x, 47 pages) : color illustrations, color maps |
| Collana | DHS analytical studies |
| Soggetto topico |
Malaria - Africa, Sub-Saharan - Prevention
Malaria - Treatment - Africa, Sub-Saharan Pregnancy - Complications - Africa, Sub-Saharan Malaria - Prevention Malaria - Treatment Pregnancy - Complications |
| Soggetto genere / forma | Statistics. |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Preventing malaria during pregnancy in Sub-Saharan Africa |
| Record Nr. | UNINA-9910711980803321 |
|
Florey Lia
|
||
| Calverton, Maryland, USA : , : ICF International, , 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Tratamiento del paludismo grave : manual práctico / / World Health Organization
| Tratamiento del paludismo grave : manual práctico / / World Health Organization |
| Edizione | [3rd ed.] |
| Pubbl/distr/stampa | Geneva, Switzerland : , : World Health Organization, , 2013 |
| Descrizione fisica | 1 online resource (87 p.) |
| Disciplina |
616.9
616.936206 |
| Soggetto topico |
Malaria - Complications
Malaria - Diagnosis Malaria - Treatment |
| ISBN | 92-4-069201-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; ÍNDICE; PREFACIO; INTRODUCCIÓN; PALUDISMO GRAVE POR P. FALCIPARUM; PALUDISMO GRAVE POR P. VIVAX; PALUDISMO GRAVE POR P. KNOWLESI; DIAGNÓSTICO DEL PALUDISMO; TRATAMIENTO GENERAL; CUIDADOS DE ENFERMERÍA; CARACTERÍSTICAS CLÍNICAS DEL PALUDISMO GRAVE Y TRATAMIENTO DE LAS COMPLICACIONES FRECUENTES EN NIÑOS; Paludismo grave; Características clínicas; Anamnesis; Evaluación inicial; Pruebas de laboratorio inmediatas; Medidas de emergencia; Tratamiento del niño inconsciente; Paludismo cerebral; Características clínicas; Tratamiento; Anemia; Características clínicas; Tratamiento
Disnea (acidosis)Características clínicas; Tratamiento; Hipoglucemia; Características clínicas; Tratamiento; Choque; Características clínicas; Tratamiento; Deshidratación y trastornos electrolíticos; Características clínicas; Tratamiento; Niños incapaces de retener la medicación oral; Seguimiento tras el alta de los niños con paludismo grave; Fármacos antipalúdicos; CARACTERÍSTICAS CLÍNICAS DEL PALUDISMO GRAVE Y TRATAMIENTO DE LAS COMPLICACIONES EN ADULTOS; Paludismo cerebral; Características clínicas; Tratamiento; Anemia; Características clínicas; Tratamiento; Lesiones renales agudas Características clínicasTratamiento; Hipoglucemia; Características clínicas; Tratamiento; Acidosis metabólica; Signos clínicos de acidosis; Tratamiento; Edema pulmonar; Características clínicas; Tratamiento; Choque; Características clínicas; Tratamiento; Sangrado anormal y coagulación intravascular diseminada; Características clínicas; Tratamiento; Hemoglobinuria; Características clínicas; Tratamiento; Fármacos antipalúdicos; CARACTERÍSTICAS CLÍNICAS ESPECIALES DEL PALUDISMO GRAVE EN EL EMBARAZO Y SU TRATAMIENTO; Paludismo grave; Características clínicas; Tratamiento; Hipoglucemia Características clínicas (véase la página 48)Tratamiento; Edema pulmonar; Características clínicas; Tratamiento; Anemia; Características clínicas; Tratamiento; Fármacos antipalúdicos; INDICADORES PRONÓSTICOS EN EL PALUDISMO GRAVE POR P. FALCIPARUM; Indicadores clínicos; Indicadores de laboratorio; ERRORES DIAGNÓSTICOS Y TERAPÉUTICOS FRECUENTES; Errores diagnósticos; Errores terapéuticos; ANEXO 1. LECTURAS RECOMENDADAS; ANEXO 2. MIEMBROS DEL COMITÉ DE EXAMEN; ANEXO 3. REALIZACIÓN E INTERPRETACIÓN DE LAS PRUEBAS DIAGNÓSTICAS RÁPIDAS; ANEXO 4. NOTAS SOBRE LOS FÁRMACOS ANTIPALÚDICOS ANEXO 5. ESCALAS DE COMA5a. escala de coma de blantyre para niños; 5b. escala de glasgow del coma (para adultos y niños de más de 5 años); ANEXO 6. ADMINISTRACIÓN DE INFUSIONES INTRAÓSEAS EN NIÑOS; ANEXO 7. MEDICIÓN DE LA PRESIÓN VENOSA YUGULAR; ANEXO 8. DIÁLISIS PERITONEAL; ANEXO 9. CÁLCULO DEL VOLUMEN DE LOS LÍQUIDOS DE MANTENIMIENTO Y DE LAS TRANSFUSIONES DE SANGRE |
| Record Nr. | UNINA-9910787175103321 |
| Geneva, Switzerland : , : World Health Organization, , 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Tratamiento del paludismo grave : manual práctico / / World Health Organization
| Tratamiento del paludismo grave : manual práctico / / World Health Organization |
| Edizione | [3rd ed.] |
| Pubbl/distr/stampa | Geneva, Switzerland : , : World Health Organization, , 2013 |
| Descrizione fisica | 1 online resource (87 p.) |
| Disciplina |
616.9
616.936206 |
| Soggetto topico |
Malaria - Complications
Malaria - Diagnosis Malaria - Treatment |
| ISBN | 92-4-069201-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; ÍNDICE; PREFACIO; INTRODUCCIÓN; PALUDISMO GRAVE POR P. FALCIPARUM; PALUDISMO GRAVE POR P. VIVAX; PALUDISMO GRAVE POR P. KNOWLESI; DIAGNÓSTICO DEL PALUDISMO; TRATAMIENTO GENERAL; CUIDADOS DE ENFERMERÍA; CARACTERÍSTICAS CLÍNICAS DEL PALUDISMO GRAVE Y TRATAMIENTO DE LAS COMPLICACIONES FRECUENTES EN NIÑOS; Paludismo grave; Características clínicas; Anamnesis; Evaluación inicial; Pruebas de laboratorio inmediatas; Medidas de emergencia; Tratamiento del niño inconsciente; Paludismo cerebral; Características clínicas; Tratamiento; Anemia; Características clínicas; Tratamiento
Disnea (acidosis)Características clínicas; Tratamiento; Hipoglucemia; Características clínicas; Tratamiento; Choque; Características clínicas; Tratamiento; Deshidratación y trastornos electrolíticos; Características clínicas; Tratamiento; Niños incapaces de retener la medicación oral; Seguimiento tras el alta de los niños con paludismo grave; Fármacos antipalúdicos; CARACTERÍSTICAS CLÍNICAS DEL PALUDISMO GRAVE Y TRATAMIENTO DE LAS COMPLICACIONES EN ADULTOS; Paludismo cerebral; Características clínicas; Tratamiento; Anemia; Características clínicas; Tratamiento; Lesiones renales agudas Características clínicasTratamiento; Hipoglucemia; Características clínicas; Tratamiento; Acidosis metabólica; Signos clínicos de acidosis; Tratamiento; Edema pulmonar; Características clínicas; Tratamiento; Choque; Características clínicas; Tratamiento; Sangrado anormal y coagulación intravascular diseminada; Características clínicas; Tratamiento; Hemoglobinuria; Características clínicas; Tratamiento; Fármacos antipalúdicos; CARACTERÍSTICAS CLÍNICAS ESPECIALES DEL PALUDISMO GRAVE EN EL EMBARAZO Y SU TRATAMIENTO; Paludismo grave; Características clínicas; Tratamiento; Hipoglucemia Características clínicas (véase la página 48)Tratamiento; Edema pulmonar; Características clínicas; Tratamiento; Anemia; Características clínicas; Tratamiento; Fármacos antipalúdicos; INDICADORES PRONÓSTICOS EN EL PALUDISMO GRAVE POR P. FALCIPARUM; Indicadores clínicos; Indicadores de laboratorio; ERRORES DIAGNÓSTICOS Y TERAPÉUTICOS FRECUENTES; Errores diagnósticos; Errores terapéuticos; ANEXO 1. LECTURAS RECOMENDADAS; ANEXO 2. MIEMBROS DEL COMITÉ DE EXAMEN; ANEXO 3. REALIZACIÓN E INTERPRETACIÓN DE LAS PRUEBAS DIAGNÓSTICAS RÁPIDAS; ANEXO 4. NOTAS SOBRE LOS FÁRMACOS ANTIPALÚDICOS ANEXO 5. ESCALAS DE COMA5a. escala de coma de blantyre para niños; 5b. escala de glasgow del coma (para adultos y niños de más de 5 años); ANEXO 6. ADMINISTRACIÓN DE INFUSIONES INTRAÓSEAS EN NIÑOS; ANEXO 7. MEDICIÓN DE LA PRESIÓN VENOSA YUGULAR; ANEXO 8. DIÁLISIS PERITONEAL; ANEXO 9. CÁLCULO DEL VOLUMEN DE LOS LÍQUIDOS DE MANTENIMIENTO Y DE LAS TRANSFUSIONES DE SANGRE |
| Record Nr. | UNINA-9910813793903321 |
| Geneva, Switzerland : , : World Health Organization, , 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
